Luisa Manning

884 total citations
28 papers, 299 citations indexed

About

Luisa Manning is a scholar working on Oncology, Biotechnology and Immunology. According to data from OpenAlex, Luisa Manning has authored 28 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Biotechnology and 10 papers in Immunology. Recurrent topics in Luisa Manning's work include Cancer Research and Treatments (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immunotherapy and Immune Responses (9 papers). Luisa Manning is often cited by papers focused on Cancer Research and Treatments (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immunotherapy and Immune Responses (9 papers). Luisa Manning collaborates with scholars based in United States, Germany and Spain. Luisa Manning's co-authors include John Nemunaitis, Laura Stanbery, Phylicia Aaron, Ernest Bognar, Gladice Wallraven, Staci Horvath, Rodney P. Rocconi, Neil Senzer, Minal Barve and Robert L. Coleman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Luisa Manning

28 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luisa Manning United States 12 199 117 111 71 41 28 299
Gladice Wallraven United States 11 206 1.0× 109 0.9× 119 1.1× 45 0.6× 64 1.6× 19 297
Staci Horvath United States 10 174 0.9× 107 0.9× 89 0.8× 37 0.5× 43 1.0× 14 248
Ernest Bognar United States 9 155 0.8× 92 0.8× 53 0.5× 48 0.7× 15 0.4× 23 187
Malcolm Farquharson United Kingdom 3 138 0.7× 88 0.8× 112 1.0× 56 0.8× 8 0.2× 6 255
Hao Ran United States 3 105 0.5× 41 0.4× 93 0.8× 112 1.6× 19 0.5× 4 236
Ngar‐Yee Huen United States 5 138 0.7× 223 1.9× 205 1.8× 25 0.4× 35 0.9× 5 388
E. Hitt Nichols United States 3 231 1.2× 96 0.8× 83 0.7× 91 1.3× 20 0.5× 5 267
Kanwaldeep Kaur Rasila United States 5 112 0.6× 74 0.6× 239 2.2× 27 0.4× 17 0.4× 9 345
Meghan Travers United States 3 102 0.5× 150 1.3× 222 2.0× 14 0.2× 19 0.5× 7 326
Yusi Fang United States 5 124 0.6× 146 1.2× 93 0.8× 19 0.3× 17 0.4× 12 270

Countries citing papers authored by Luisa Manning

Since Specialization
Citations

This map shows the geographic impact of Luisa Manning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa Manning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa Manning more than expected).

Fields of papers citing papers by Luisa Manning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa Manning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa Manning. The network helps show where Luisa Manning may publish in the future.

Co-authorship network of co-authors of Luisa Manning

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa Manning. A scholar is included among the top collaborators of Luisa Manning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa Manning. Luisa Manning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Anderson, Peter M., Brian D. Crompton, Kelly Klega, et al.. (2023). Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research. 29(9). 1689–1697. 15 indexed citations
3.
Rocconi, Rodney P., Laura Stanbery, Min Tang, et al.. (2022). ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. SHILAP Revista de lepidopterología. 2(1). 106–106. 8 indexed citations
4.
Barve, Minal, Phylicia Aaron, Luisa Manning, et al.. (2022). Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights Oncology. 16. 1363231461–1363231461. 15 indexed citations
5.
Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 161(3). 676–680. 26 indexed citations
6.
Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 163(3). 459–464. 14 indexed citations
7.
Adams, Ned, Laura Stanbery, Luisa Manning, et al.. (2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 9(10). 1201–1201. 6 indexed citations
8.
Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2021). Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Therapy. 29(3-4). 369–382. 20 indexed citations
9.
Rocconi, Rodney P., Laura Stanbery, Luciana Madeira da Silva, et al.. (2021). Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines. 9(8). 894–894. 12 indexed citations
10.
Morand, Susan, Rachel Royfman, Monika Devanaboyina, et al.. (2020). Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer. 12(1). 38–53. 47 indexed citations
11.
Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2020). A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 3002–3002. 10 indexed citations
12.
Rocconi, Rodney P., Elizabeth A. Grosen, Sharad Ghamande, et al.. (2020). Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 6017–6017. 3 indexed citations
13.
Oh, Jonathan, Minal Barve, Neil Senzer, et al.. (2020). Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecologic Oncology Reports. 34. 100648–100648. 19 indexed citations
14.
Rao, Donald D., Xiuquan Luo, Zhaohui Wang, et al.. (2018). KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. PLoS ONE. 13(5). e0193644–e0193644. 10 indexed citations
15.
Manning, Luisa, Minal Barve, Gladice Wallraven, et al.. (2017). Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. 2(1). 3 indexed citations
16.
Anderson, Peter M., Minal Barve, Jonathan Gill, et al.. (2017). A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS11079–TPS11079. 1 indexed citations
17.
Oh, Jonathan, Minal Barve, Devansu Tewari, et al.. (2017). Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS5604–TPS5604. 4 indexed citations
18.
Manning, Luisa, et al.. (2016). Innovative Exploratory Clinical Approaches for Relapsed and/or Refractory Metastatic Ewing’s Sarcoma. 1(1). 1 indexed citations
19.
Christmas, T.I., et al.. (1993). The role of platelet derived growth factor in the growth of human malignant mesothelioma. European Respiratory Review. 3(11). 189–191. 9 indexed citations
20.
Christmas, T.I., et al.. (1993). Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. European Respiratory Review. 3(11). 192–194. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gladice Wallraven Breakdown of academic impact, for papers by Staci Horvath Breakdown of academic impact, for papers by Ernest Bognar Breakdown of academic impact, for papers by Malcolm Farquharson Breakdown of academic impact, for papers by Hao Ran Breakdown of academic impact, for papers by Ngar‐Yee Huen Breakdown of academic impact, for papers by E. Hitt Nichols Breakdown of academic impact, for papers by Kanwaldeep Kaur Rasila Breakdown of academic impact, for papers by Meghan Travers Breakdown of academic impact, for papers by Yusi Fang
Rankless by CCL
2026